Latest news

1 year 5 months ago
The Financial Review Group, which was established by the Scottish Government following the publication of the Penrose Inquiry earlier this year, has today submitted to the Scottish Government its recommendations for the reform of the current financial support arrangements for people affected by infected NHS blood and blood products.
1 year 5 months ago
The NHS has to respond to the financial and demographic challenges that threaten its long-term sustainability. The Hepatitis C Trust is part of an expert group looking at how to tackle the increasingly urgent challenge of making our health and care services sustainable for the future. In June 2014, the culmination of this work after a year of research and consultation saw AbbVie, in partnership with the College of Medicine, launched a report on sustainable healthcare: Patient, manager, expert, individual. It made recommendations for change around three important priorities:
1 year 5 months ago
 With the new treatments approved for use on the NHS last week in final guidance released by the National Institute for Health and Care Excellence (NICE), a huge opportunity now exists to eliminate hepatitis C as a serious public health concern – if action is taken.
1 year 6 months ago
Following the release last month of provisional recommendations for access to several new treatments for hepatitis C (see The Hepatitis C Trust news story here), the National Institute for Health and Care Excellence (NICE) has today published final guidance recommending Harvoni*, Viekirax (with our without Exviera)** and Daklinza*** for treatment of people with certain genotypes of hepatitis C.
1 year 6 months ago
Kirsty Williams, Welsh Assembly Member for Brecon and Radnorshire and leader of the Welsh Liberal Democrats, visited University Hospital of Wales in Cardiff on 18th November to find out about the treatment services on offer to people in Cardiff and the surrounding areas with hepatitis C, as well as to find out more about the new Welsh Liver Disease Delivery Plan.
1 year 6 months ago
This year sees the first European HIV-Hepatitis Testing Week, taking place between 20th - 27th November, with the inclusion of hepatitis an acknowledgment of how important tackling hepatitis C, a leading cause of liver disease, is to public health. Effective testing and screening are central not just to our ability to provide treatment for those living with hepatitis C but also to limit the number of infections. Recent medical advances mean hepatitis C can now be treated quickly, effectively and with limited side effects.
1 year 7 months ago
A report by the Advisory Council on the Misuse of Drugs (ACMD) addresses the treatment of hepatitis C amongst people who use heroin. It highlights how hepatitis C could be eliminated amongst people in drug treatment and how the variations in access to treatment for hepatitis C reduces the likelihood of successful outcomes from drug treatment.
1 year 7 months ago
Darren Millar, Welsh Assembly Member for Clwyd West and Shadow Minister for Health and Social Services, visited Wrexham Maelor Hospital last Friday to find out more about the treatment services on offer for people in North Wales with hepatitis C, as well as other liver disease patients.
1 year 7 months ago
The flu vaccine is provided free by the NHS to those living with serious health conditions as part of the NHS’s ‘Stay Well this Winter’ campaign. For most healthy people, flu is an unpleasant but usually self-limiting disease with recovery taking up to a week. People with flu are approximately 11 times more likely to die if they have an underlying health condition than if they don’t. Chief Medical Officer, Professor Dame Sally Davies, said:
1 year 7 months ago
The National Institute of Clinical Excellence (NICE) have announced which of the new treatments will be made available by the NHS to people living with hepatitis C. The NICE decisions will widen access to a range of new all-oral, direct acting antiviral treatments beyond those patients with decompensated cirrhosis who were treated from 2014 under the Early Access Scheme, and beyond those with cirrhosis who were given access to new treatments earlier this year.

Pages